Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru

BMC Public Health

Table 5 Cost-effectiveness of PCVs (per QALY gained), in increasing order of QALYs

	QALYs	Cost^a	Differences vs no vaccine			Incremental differences vs PCV-7 scenario
	QALYs	Cost^a	QALYs	Cost^a	ICER	QALYs	Cost^a	ICER
No vaccine	11,586,536	23,570,416	-	-	-	-	-	-
PCV-7	11,590,206	45,641,050	3,670	22,070,634	6,014	-	-	-
PCV-13	11,590,925	46,952,004	4,389	23,381,588	5,327	719	1,310,954	Dominated
PHiD-CV	11,590,975	43,544,180	4,439	19,973,764	4,500	50	−3,407,824	−2,727

^aCosts in 2009 US$ (discounted data).
ICER, incremental cost-effectiveness ratio; PCV, pneumococcal conjugate vaccine; PCV-7, 7-valent pneumococcal conjugate vaccine; PCV-13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine; QALY, quality-adjusted life year.

ISSN: 1471-2458